Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'

被引：1
|
作者：
den Broeder, Alfons A. [1 ]
van den Bemt, Bart J. F. [2 ]
机构：
[1] Sint Maartensklin, Reumatol, NL-6522 JV Nijmegen, Netherlands
[2] Sint Maartensklin, Pharm, Nijmegen, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷 / 10期
关键词：
D O I：
10.1136/annrheumdis-2017-212579
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 40 条
  • [1] Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al
    L'Ami, Merel J.
    Krieckaert, Charlotte L. M.
    Nurmohamed, Michael T.
    van Vollenhoven, Ronald F.
    Rispens, Theo
    Boers, Maarten
    Wolbink, Gerrit Jan
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (10)
  • [2] Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial
    l'Ami, Merel J.
    Krieckaert, Charlotte L. M.
    Nurmohamed, Michael T.
    van Vollenhoven, Ronald F.
    Rispens, Theo
    Boers, Maarten
    Wolbink, Gerrit Jan
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (04) : 484 - 487
  • [3] Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial
    Tamai, Hiroya
    Ikeda, Kei
    Miyamoto, Toshiaki
    Taguchi, Hiroaki
    Kuo, Chang-Fu
    Shin, Kichul
    Hirata, Shintaro
    Okano, Yutaka
    Sato, Shinji
    Yasuoka, Hidekata
    Kuwana, Masataka
    Ishii, Tomonori
    Kameda, Hideto
    Kojima, Toshihisa
    Taninaga, Takehiro
    Mori, Masahiko
    Miyagishi, Hideaki
    Sato, Yasunori
    Tsai, Wen-Chan
    Takeuchi, Tsutomu
    Kaneko, Yuko
    LANCET RHEUMATOLOGY, 2023, 5 (04): : 215 - 224
  • [4] A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial
    Van Linschoten, R.
    Jansen, F.
    Pauwels, R.
    Smits, L.
    Atsma, F.
    Kievit, W.
    de Jong, D.
    de Vries, A.
    Boekema, P.
    West, R.
    Bodelier, A.
    Gisbertz, I.
    Wolfhagen, F.
    Romkens, T.
    Lutgens, M.
    van Bodegraven, A.
    Oldenburg, B.
    Pierik, M.
    Russel, M.
    de Boer, N.
    Mallant-Hent, R.
    ter Borg, P.
    van der Meulen-de Jong, A.
    Jansen, J.
    Jansen, S.
    Tan, A.
    van der Woude, C. J.
    Hoentjen, F.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 655 - 658
  • [5] Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
    van Herwaarden, Noortje
    van der Maas, Aatke
    Minten, Michiel J. M.
    van den Hoogen, Frank H. J.
    Kievit, Wietske
    van Vollenhoven, Ronald F.
    Bijlsma, Johannes W. J.
    van den Bemt, Bart J. F.
    den Broeder, Alfons A.
    BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [6] Comment on Miki et al.: Randomized open-label non-inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain
    Toda, Katsuhiro
    JOURNAL OF ORTHOPAEDIC SCIENCE, 2019, 24 (01) : 189 - 189
  • [7] Comment on "Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial"
    Ferreira, Daniel
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2012, 31 (03) : 263 - 264
  • [8] Comment on Miki et al.: Randomized open-label non-inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain Reply
    Miki, Kenji
    Ikemoto, Tatsunori
    Hayashi, Kazuhiro
    Arai, Young-Chang
    Sekiguchi, Miho
    Shi, Kenrin
    Ushida, Takahiro
    JOURNAL OF ORTHOPAEDIC SCIENCE, 2019, 24 (01) : 190 - 191
  • [9] A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial
    van Linschoten, Reinier C. A.
    Jansen, Fenna M.
    Pauwels, Renske W. M.
    Smits, Lisa J. T.
    Atsma, Femke
    Kievit, Wietske
    de Jong, Dirk J.
    de Vries, Annemarie C.
    Boekema, Paul J.
    West, Rachel L.
    Bodelier, Alexander G. L.
    Gisbertz, Ingrid A. M.
    Wolfhagen, Frank H. J.
    Romkens, Tessa E. H.
    Lutgens, Maurice W. M. D.
    van Bodegraven, Adriaan A.
    Oldenburg, Bas
    Pierik, Marieke J.
    Russel, Maurice G. V. M.
    de Boer, Nanne K.
    Mallant-Hent, Rosalie C.
    ter Borg, Pieter C. J.
    van der Meulen-de Jong, Andrea E.
    Jansen, Jeroen M.
    Jansen, Sita V.
    Tan, Adrianus C. I. T. L.
    van der Woude, C. Janneke
    Hoentjen, Frank
    DIGESTIVE DISEASES AND SCIENCES, 2024, : 2165 - 2174
  • [10] Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial
    Porter, Duncan
    van Melckebeke, Jurgen
    Dale, James
    Messow, C. Martina
    McConnachie, Alexander
    Walker, Andrew
    Munro, Robin
    McLaren, John
    McRorie, Euan
    Packham, Jon
    Buckley, Christopher D.
    Harvie, John
    Taylor, Peter
    Choy, Ernest
    Pitzalis, Costantino
    McInnes, Iain B.
    LANCET, 2016, 388 (10041): : 239 - 247
1234